Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 13/20 | 0.43 |
| ▸ | THRB | P10828 | 13/20 | 0.43 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | CASP9 | P55211 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24133324 | 0.92 | THRA (0.43) | THRATHRBESR1CASP3CASP7 | |
| SCHEMBL24133194 | 0.90 | THRA (0.46) | THRATHRBESR1CASP3CASP7 | |
| SCHEMBL24133185 | 0.88 | THRB (0.53) | THRATHRB | |
| SCHEMBL30529704 | 0.87 | THRA (0.48) | THRATHRBESR1CASP3CASP7 | |
| SCHEMBL24133184 | 0.87 | THRA (0.48) | THRATHRBESR1CASP3CASP7 | |
| SCHEMBL24133192 | 0.85 | THRA (0.42) | THRATHRBESR1CASP3CASP7 | |
| SCHEMBL23409571 | 0.80 | THRB (0.49) | THRATHRBESR1CASP3CASP7 | |
| SCHEMBL22095708 | 0.79 | THRB (0.63) | THRATHRB | |
| SCHEMBL25898234 | 0.78 | THRA (0.42) | THRATHRBESR1 | |
| SCHEMBL23409562 | 0.78 | THRB (0.56) | THRATHRBESR1CASP3CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242473-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242473-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242473-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2021257834-A1 | THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242473-A1 | THYROMIMETICS | TPO, THOP1, THRB | THRA 6/4885THRB 3/4885ESR1 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.